RT Journal Article
SR Electronic
T1 Efficacy assessment of newly-designed and locally-produced filtering facemasks during the SARS-CoV-2 pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.04.20188185
DO 10.1101/2020.09.04.20188185
A1 Bob Boogaard
A1 Ali Tas
A1 Joep Nijssen
A1 Freek Broeren
A1 John van der Dobbelsteen
A1 Vincent Verhoeven
A1 Jip Pluim
A1 Sing Dekker
A1 Eric Snijder
A1 Martijn van Hemert
A1 Sander Herfst
YR 2020
UL http://medrxiv.org/content/early/2020/09/07/2020.09.04.20188185.abstract
AB The SARS-CoV-2 pandemic resulted in shortages of production and test capacity of FFP2-respirators. Such facemasks are required to be worn by healthcare professionals when performing aerosol-generating procedures on COVID-19 patients. In response to the high demand and short supply, we designed three models of facemasks that are suitable for local production. As these facemasks should meet the requirements of an FFP2-certified facemask, the newly-designed facemasks were tested on the filtration efficiency of the filter material, inward leakage, and breathing resistance with custom-made experimental setups. In these tests, the locally-produced facemasks were benchmarked against a commercial FFP2 facemask. Furthermore, the protective capacity of the facemasks was tested for the first time with coronavirus-loaded aerosols under physiologically relevant conditions. This multidisciplinary effort resulted in the design and production of facemasks that meet the FFP2 requirements, and which can be mass-produced at local production facilities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the NIH/NIAID (contract number HHSN272201400008C) and European Unions Horizon 2020 research and innovation program VetBioNet (grant agreement No 731014). Part of this research was supported by the Leiden University Fund (LUF) the Bontius Foundation and donations from the crowdfunding initiative Wake up to corona. S.H. was funded in part by an NWO VIDI grant (contact number 91715372). Part of this research was supported by ZonMw initiative Creative solutions against CoVID-19 (5001-0013).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No clinical trial has been performed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll obtained data are in the manuscript file and supplemental data file